Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings
Top Cited Papers
- 1 April 2002
- journal article
- review article
- Published by Elsevier BV in Seminars in Nuclear Medicine
- Vol. 32 (2), 133-140
- https://doi.org/10.1053/snuc.2002.31027
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- [177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- [177Lu-DOTA0,Tyr3]octreotate for somatostatin receptor-targeted radionuclide therapyInternational Journal of Cancer, 2001
- Receptor-mediated Radionuclide Therapy with 90Y-DOTA-D-Phe1-Tyr3-Octreotide: Preliminary Report in Cancer PatientsCancer Biotherapy & Radiopharmaceuticals, 1999
- Yttrium-90 DOTATOC: first clinical resultsEuropean Journal of Nuclear Medicine and Molecular Imaging, 1999
- Somatostatin and Its Receptor FamilyFrontiers in Neuroendocrinology, 1999
- Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liverInternational Journal of Cancer, 1999
- The somatostatin receptor-targeted radiotherapeutic [ 90 Y-DOTA- d Phe 1 ,Tyr 3 ]octreotide ( 90 Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 1998
- Yttrium-90-labelled somatostatin-analogue for cancer treatmentThe Lancet, 1998
- The somatostatin receptor familyLife Sciences, 1995
- Radiotherapy with a Radiolabeled Somatostatin Analogue, [111In‐DTPA‐d‐Phe1]‐OctreotideAnnals of the New York Academy of Sciences, 1994